Geron Taps Novartis Veteran as Chief Business Officer to Drive Hematology Growth
Event summary
- Chinmaya Rath appointed Chief Business Officer at Geron on July 13, 2026.
- Rath brings 25 years of biopharma leadership experience, including roles at Novartis and Cellworks.
- Geron aims to leverage Rath's expertise to maximize the global value of RYTELO (imetelstat).
- RYTELO is approved for lower-risk myelodysplastic syndromes in the U.S. and EU.
The big picture
Geron's appointment of Chinmaya Rath underscores its push to solidify its position in the hematology space. With RYTELO already approved and a pivotal Phase 3 trial underway for myelofibrosis, the move signals Geron's intent to capitalize on its first-in-class telomerase inhibitor. Rath's extensive experience in high-impact strategic initiatives at Novartis and other biopharma leaders positions him to drive operational excellence and commercial success.
What we're watching
- Commercial Execution
- How Rath's strategic insights will accelerate RYTELO's market penetration in hematology.
- Pipeline Expansion
- Whether Geron can sustain its growth trajectory through opportunistic innovation under Rath's leadership.
- Regulatory Milestones
- The pace at which imetelstat gains approvals for additional indications beyond lower-risk MDS.
Related topics